<DOC>
	<DOCNO>NCT01802931</DOCNO>
	<brief_summary>The study determine effect 400 mg daily ketoconazole steady state pharmacokinetics single oral dose GSK239512 young healthy volunteer . Ketoconazole strong inhibitor CYP3A4 , involve metabolism drug . A two-cohort design apply cohort 1 aim provide first estimate interaction potential GSK239512 ketoconazole term pharmacokinetic parameter small number subject . Data Cohort 1 inform decision dose use Cohort 2 , large number subject expose GSK239512 without ketoconazole . The target maximum exposure aim similar exposure single dose 80 mcg GSK239512 without CYP3A4 inhibition . In summary , result study help estimate maximum increase exposure GSK239512 concomitant use strong CYP3A4 inhibitor help define subsequent dose strategy around GSK239512 co-medications potential inhibit CYP3A4 .</brief_summary>
	<brief_title>GSK239512 DDI Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Histamine H3 Antagonists</mesh_term>
	<criteria>1 . Male 18 45 year age inclusive , time signing informed consent . 2 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . 3 . ALT , alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 4 . QTcF &lt; 450 msec . 5 . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication 1 month postlast dose GSK239512 . 6 . Body weight &gt; 50 kg , body mass index ( BMI ) 19.0 29.9 kg/m2 inclusive . 7 . Capable give informed consent comply study requirement timetable . 1 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen 2 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 3 . A positive prestudy drug/alcohol screen . 4 . A positive test Human Immunodeficiency Virus ( HIV ) antibody . 5 . History alcohol consumption exceed , average , 21 drinks/week men ( 1 drink = 100 mL wine 240 mL beer 30 mL hard liquor Australia ) within 6 month first dose study medication . 6 . History smoking cigarette use tobacco product nicotinecontaining product ( include nicotine patch ) within 3 month screen . 7 . The subject participate clinical trial receive investigational product within 30 day 5 half life ( whichever longer ) prior first dose day current study . 8 . Exposure four new chemical entity within 12 month prior first dose day . 9 . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 10 . History sensitivity ketoconazole , excipients contain GSK239512 Nizoral , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 11 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 12 . Unwillingness inability follow procedure outline protocol . 13 . Subject mentally legally incapacitate . 14 . Have use following medication within last 30 day 5 halflives ( whichever longer ) prior screen able discontinue use throughout participation clinical trial : Any CNS stimulant ( e.g. , modafinil , dexamphetamine , methylphenidate ) . Known potent Pglycoprotein inhibitor ( e.g . itraconazole , ketoconazole , cyclosporin , loperamide , diltiazem , verapamil , spironolactone , quinidine , bepridil , quinine , carvedilol ) . Known potent inhibitor inducer CYP3A4 enzyme ( see Appendix 3 ) . CNSpenetrant antihistamine ( e.g . bromopheniramine , chlorpheniramine , clemastine , diphenhydramine , hyrdoxyzine ) Any medicine contraindication Nizoral ( see Appendix 4 ) . 15 . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . 16 . The subject history significant psychiatric illness . 17 . Presence history hallucination , judgement investigator , may increase safety risk subject . 18 . At risk suicide , indicate : A documented history attempt suicide significant suicidal ideation 6 month precede screen visit , OR If investigator 's judgment subject risk suicide attempt base screen visit assessment , include CSSRS . 19 . Diagnosis type epilepsy 20 . Night shift worker within 4 week first dose 21 . Presence significant routine sleep disturbance negative impact quality life , judgement investigator , may increase risk tolerability issue dose escalation . Examples significant sleep disturbance may : severe insomnia , nocturnal wandering , confusion , disorientation , agitation , vivid dream .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GSK239512</keyword>
	<keyword>H3 receptor antagonist</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>ketoconazole</keyword>
</DOC>